Logo
search
  • Analytics
  • Backtesting
  • Options
  • Resources
  • Go Prime Go Prime
  • Menu
  • Menu

AARTIDRUGS

Current Price

329.156.75 (2.09%)

|

H: 331.05

L: 325.85

  • BSE: 524348
  • |
  • NSE: AARTIDRUGS
  • |
  • ISIN: INE767A01016
  • |
  • INDUSTRY: Pharmaceuticals

Open Price

330.6

Prev. Close

322.4

Price Table

* Prices are based on daily market changes.
DateOpenHighLowCloseVolumeDelivery %20-Day sma50-Day sma200-Day sma
11 Apr, 2025330.60331.05325.85329.151,16,42950.07341.30368.95463.15
09 Apr, 2025330.30330.30320.20322.4072,00443.05342.55370.15464.05
08 Apr, 2025327.50332.80323.80330.301,17,75034.31344.60371.70465.05
07 Apr, 2025317.00324.95312.00321.751,80,56137.67346.65373.30466.00
04 Apr, 2025348.50348.65327.60332.902,86,14654.66349.00375.15467.00
03 Apr, 2025342.00359.35341.00348.502,52,75732.68350.55376.85467.95
02 Apr, 2025346.55346.55336.10342.501,99,37955.30350.65378.35468.80

Day High Low Range

TimeLowestHighestVolume
09.30 AM326.30331.0511247.00
09.45 AM326.30331.0516375.00
10 AM326.30331.0521171.00
11 AM325.85331.0533697.00
12 PM325.85331.0543923.00
1 PM325.85331.0562788.00
2 PM325.85331.0574308.00
3 PM325.85331.05101475.00

Past Performance & Moving Averages

Day’sLow high rangeSMAStock performanceNifty performance
10 DAY
312.00
-
360.00
336.4-4.64%-3.19%
20 DAY
312.00
-
367.10
341.32-8.94%-4.41%
50 DAY
312.00
-
433.00
368.94-14.9%-1.81%
100 DAY
312.00
-
497.60
405.71-28.99%-4.94%
200 DAY
312.00
-
635.00
463.15-36.54%-13.34%
YTD
312.00
-
476.75
386.17-28.99%-4.94%
52 Week
312.00
-
635.00
469.57-34.8%-6.25%

PIVOT POINTS

NAMES4S3S2S1PIVOT POINTSR1R2R3R4
CLASSIC-308.20314.20318.30324.30328.40334.40338.50-
WOODIE‘S--313.72317.35323.82327.45333.93--
FIBONACCI-314.20318.06320.44324.30328.16330.54334.40-
CAMARILLA316.84319.62320.55321.47-323.33324.25325.18327.95

CPR Levels

LTP: 329.15
PDH: 330.30
PDL: 320.20
S4
318.28
S3
321.12
S2
323.48
S1
326.32
| CPR |
BC: 328.45
P: 328.68
TC: 328.92
R1
331.52
R2
333.88
R3
336.72
R4
339.08
  • AARTIDRUGS is currently trading Above CPR levels which signifies Bullishness.
  • Today's CPR is comparatively Narrower and likely to make a trending move today.
  • Day's opening range is 326.3 ~ 331.05.
  • Price is currently trading Inside the day's opening range.

Trend Analysis

Short term trend: Down
Medium term trend: Down
Long term trend: Down

Key Data

Market capBook valuestock p/eDividend yieldroceroesales growth (3Y)face value (3Y)
3024.07 CR.139.0028.300.19% 14.80% 13.90%5.00% 10.00

Profile

Aarti Drugs Limited is an Indian pharmaceutical company that was established in 1984. The company specializes in the manufacture and sale of bulk drugs, intermediates, and specialty chemicals. Its products are sold both in India and overseas, and the company has a strong presence in the domestic and international markets.

In terms of financials, Aarti Drugs has shown steady growth over the years, with revenue and profit increasing year-on-year. The company's revenue primarily comes from the sale of bulk drugs, intermediates, and specialty chemicals.

Here is a brief SWOT analysis for Aarti Drugs:

Strengths:

  • Strong R&D capabilities and expertise in the pharmaceutical industry
  • Wide product portfolio with a focus on specialty chemicals
  • Strong distribution network in India and overseas markets

Weaknesses:

  • Dependence on a limited number of key customers
  • Vulnerability to fluctuations in the price and availability of raw materials
  • Exposure to regulatory risks and potential liabilities

Opportunities:

  • Expansion into new geographies, both domestically and internationally
  • Increasing demand for specialty chemicals in the pharmaceutical industry
  • Development of new, high-value products through R&D investments

Threats:

  • Competition from larger and well-established pharmaceutical companies
  • Changes in government regulations and policies, such as taxes and import duties
  • Intellectual property risks, including patent infringement and other legal disputes.

Please note that this is a general analysis and may not accurately reflect the current state of the company. It's important to conduct thorough research and consult with a financial advisor before making any investment decisions.